Phase II
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look.
Gilead has announced they are pulling cancer drug Zydelig (idelalisib) off the market for certain types of cancer after failing to complete follow-up clinical trials to confirm efficacy and safety.
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.
The Glycogen Storage Disease Program at Connecticut Children’s and UConn Health reported success in a Phase I/II trial of a gene therapy for GSD-Ia.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
A checkpoint inhibitor under development from China’s CStone Pharmaceuticals hit the mark in a Phase III non-small cell lung cancer study.
The new pancreatic cancer vaccine from ImmunityBio shows very promising results. Here’s what you need to know about the vaccine and its result from the tests.
Moderna is poised to commercialize its COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against the RSV.
The agency recommended another clinical trial be conducted to confirm the data from the study on the 3.2-mg dose of the intranasal carbetocin for Prader-Willi syndrome.
Amagma Therapeutics announced a licensing agreement with Innovent Biologics for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC Platform.
PRESS RELEASES